Loading organizations...
Based in Boulder, Colorado, Cheribundi manufactures tart cherry juice beverages and concentrates designed to aid athletic recovery, reduce muscle soreness, and decrease joint inflammation. The private manufacturer supplies its natural performance wellness products to a customer base of over 2,000 professional and collegiate athletic teams across the country. The company developed its original tart cherry juice formula in collaboration with food scientist Olga Padilla-Zakour at Cornell University, and it currently partners with the American Sports & Performance Dietitians Association. To support ongoing operations and product line expansion, including the recent introduction of specialized juice concentrates in pouches, the enterprise secured a $15 million Series B venture capital funding round led by Emil Capital Partners. Originally operating under the name CherryPharm, the beverage business was founded in 2004 by former Wall Street banker John Davey.
Cheribundi has raised $20.0M across 2 funding rounds.
Cheribundi has raised $20.0M in total across 2 funding rounds.
Cheribundi is a company that produces natural tart cherry juice beverages designed primarily for sports nutrition and recovery. Its products serve active individuals, including professional and collegiate athletes, by providing a natural aid to reduce inflammation, improve sleep, and enhance muscle recovery. Cheribundi’s portfolio includes tart cherry juices, concentrates, and recently introduced Immunity and Sleep Concentrates, all formulated through a proprietary filtration process to maximize antioxidant benefits. The company has demonstrated strong growth momentum, with its products consumed by over 2,000 professional and collegiate sports teams and available nationwide across major retail channels and online[1][2][3][4][6].
Founded in 2004 by John Davey, a former Wall Street banker, Cheribundi began as CherryPharm before rebranding in 2012. The idea emerged from Davey’s collaboration with Cornell University food scientist Olga Padilla-Zakour to develop an all-natural tart cherry juice with scientifically backed health benefits. Early traction came from the recognition of tart cherry juice’s antioxidant power to aid recovery and reduce muscle soreness, which helped Cheribundi establish itself as a leader in natural sports nutrition. The company has evolved through leadership changes, manufacturing relocations to Michigan for better access to Montmorency tart cherries, and significant funding rounds, culminating in its acquisition by GoodBelly’s parent company NextFoods in 2023[1][2][5].
Cheribundi rides the growing trend of functional beverages and natural sports nutrition, capitalizing on increasing consumer demand for scientifically backed, whole-food-based health products. The timing is favorable due to rising awareness of natural recovery aids and holistic wellness, especially among athletes and health-conscious consumers. Market forces such as the expansion of the sports nutrition category, interest in plant-based and antioxidant-rich products, and the shift toward convenient, on-the-go nutrition support Cheribundi’s growth. By integrating science, athlete endorsements, and retail accessibility, Cheribundi influences the broader ecosystem by setting standards for natural performance wellness products[1][4][6].
Looking ahead, Cheribundi is poised to expand its product line, including new formats like tart cherry gummies launching in 2024, and deepen its presence in both sports and general wellness markets. Trends shaping its journey include increasing consumer preference for natural, functional ingredients and the convergence of sports nutrition with overall health and immunity support. As part of NextFoods, Cheribundi benefits from synergies with other functional food brands, enhancing innovation and distribution. Its influence is likely to grow as it continues to validate tart cherry juice’s benefits through science and athlete partnerships, potentially becoming a broader wellness staple beyond sports recovery[1][5][6].
Cheribundi has raised $20.0M in total across 2 funding rounds.
Cheribundi's investors include Emil Capital Partners.
Cheribundi has raised $20.0M across 2 funding rounds. Most recently, it raised $15.0M Series B in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2020 | $15M Series B | — | Emil Capital Partners | Announced |
| Feb 1, 2012 | $5M Series U | — | Emil Capital Partners | Announced |
